Second Time Around: Cephalon Buys Ception Based On Cinquil Data In Asthma
This article was originally published in The Pink Sheet Daily
Executive Summary
Cephalon passed on a first option to buy Ception Therapeutics, but will now acquire the company for $250 million following encouraging Phase II results.
You may also be interested in...
On The Respiratory Horizon: A Wave Of Biologics For Asthma
Several antibody drugs are in late-stage development to treat severe asthma and could reach the market in the next two years. But competition for niche subsets of patients will be fierce, and tailoring the right medications to the right patients to justify the higher cost of treatment will require advances in biomarker development.
As Cephalon Rejects Valeant Bid, Valeant Officially Goes Hostile
Valeant's offer undervalues Cephalon, its assets and its prospects, and "ignores the proven ability" of its management to maximize opportunities, Cephalon's board says.
As Cephalon Rejects Valeant Bid, Valeant Officially Goes Hostile
Valeant's offer undervalues Cephalon, its assets and its prospects, and "ignores the proven ability" of its management to maximize opportunities, Cephalon's board says.